参考文献/References:
[1]Matsushima Y, Aoyagi M, Suzuki R, et al Perioperative complications of encephaloduroarteriosynangiosis: prevention and treatment Surg Neurol,1991,36(5):343-353
[2]Deng X, Gao F, Zhang D, et al Effects of different surgical modalities on the clinical outcome of patients with moyamoya disease: a prospective cohort study. J Neurosurg,2018,128(5):1327-1337.
[3]Park SE, Kim JS, Park EK, et al. Direct versus indirect revascularization in the treatment of moyamoya disease. J Neurosurg,2018,129(2):480-489.
[4]Wang QN, Zou ZX, Wang XP, et al. Endothelial progenitor cells induce angiogenesis: a potential mechanism underlying neovascularization in encephaloduroarteriosynangiosis. Transl Stroke Res,2021,12(2):357-365.
[5]Bao XY, Fan YN, Wang QN, et al. The potential mechanism behind native and therapeutic collaterals in moyamoya. Front Neurol,2022,13:861184.
[6]Gonzalez NR, Dusick JR, Connolly M, et al. Encephaloduroarteriosynangiosis for adult intracranial arterial stenoocclusive disease: longterm singlecenter experience with 107 operations. J Neurosurg,2015,123(3):654-661.
[7]贾红芳,叶雪,赵颖,等.他汀类药物防治脑卒中的作用机理、用药指导及不良反应.中国药物滥用防治杂志,2023,29(10):1768-1770,1779.
[8]Wang QN, Bao XY, Zou ZX, et al. The role of atorvastatin in collateral circulation formation induced by encephaloduroarteriosynangiosis: a prospective trial. Neurosurg Focus,2021,51(3):E9.
[9]Gao G, Wang QN, Hao FB, et al. To explore the effectiveness of atorvastatin in the postoperative formation of collateral blood vessels after encephaloduroarteriosynangiosis in patients with moyamoya disease: a prospective doubleblind randomized controlled study. Front Neurol,2023,14:1169253.
[10]王彤,任蒙蒙,徐陆正,等.光、磁成像法探测脑胶质瘤微环境脑组织间隙结构及脑组织间液引流的变化.中国微创外科杂志,2020,20(1):46-51.
[11]Gao Y, Han H, Du J, et al. Early changes to the extracellular space in the hippocampus under simulated microgravity conditions. Sci China Life Sci,2022,65(3):604-617.
[12]Yue X, Mei Y, Zhang Y, et al. New insight into alzheimer’s disease: light reverses abetaobstructed interstitial fluid flow and ameliorates memory decline in APP/PS1 mice. Alzheimers Dement (N Y),2019,5:671-684.
[13]Cai X, He Q, Wang W, et al. Epidural pulsation accelerates the drainage of brain interstitial fluid. Aging Dis,2023,14(1):219-228.
[14]周洁,连婧阁,任秋实,等.磁示踪法在硬膜外动脉贴敷术加速丘脑组织间液引流机制研究中的应用.磁共振成像,2023,14(2):97-102.
[15]陈军,李爱民,陈震,等.血管重建手术与保守治疗出血型烟雾病的疗效分析.中国微创外科杂志,2015,15(12):1084-1087.
[16]Acker G, Fekonja L, Vajkoczy P. Surgical management of moyamoya disease. Stroke,2018,49(2):476-482.
[17]烟雾病和烟雾综合征诊断与治疗中国专家共识编写组,国家卫生计生委脑卒中防治专家委员会缺血性卒中外科专业委员会.烟雾病和烟雾综合征诊断与治疗中国专家共识(2017).中华神经外科杂志,2017,33(6):541-547.
[18]Choi JW, Chong S, Phi JH, et al. Postoperative symptomatic cerebral infarction in pediatric moyamoya disease: risk factors and clinical outcome. World Neurosurg,2020,136:e158-e164.
[19]Riordan CP, Storey A, Cote DJ, et al. Results of more than 20 years of followup in pediatric patients with moyamoya disease undergoing pial synangiosis. J Neurosurg Pediatr,2019，23（5）:586-592.
[20]Guo Q, Fan YN, Wang QN, et al. Nomogram for predicting longterm outcomes of encephaloduroarteriosynangiosis in toddlers with moyamoya disease: a longitudinal and crosssectional study. Transl Stroke Res,Published online November 9,2023.
[21]邵冰水,王国文,靳腾龙.脑硬脑膜颞浅动脉血管融通术对缺血性烟雾病儿童预后的影响.河南医学高等专科学校学报,2024,36(1):27-30.
[22]Guo Q, Pei S, Wang QN, et al. Risk factors for preoperative cerebral infarction in infants with moyamoya disease. Transl Stroke Res,Published online June 14,2023.
[23]Wang QN, Bao XY, Zhang Y, et al. Encephaloduroarteriosynangiosis for hemorrhagic moyamoya disease: longterm outcome of a consecutive series of 95 adult patients from a single center. J Neurosurg,2019,130(6):1898-1905.
[24]Duan L, Bao XY, Yang WZ, et al. Moyamoya disease in China: its clinical features and outcomes. Stroke,2012,43(1):56-60.
[25]Li JJ, Wang XP, Wang QN, et al. Longterm outcomes after conservative and EDAS treatment for 111 elderly patients with moyamoya disease: longitudinal and crosssectional study. J Neurosurg,2023，140（3）：800-808.
[26]Gao G, Hao FB, Wang QN, et al. Surgical outcomes following encephaloduroarteriosynangiosis in moyamoya disease associated with hyperhomocysteinemia. Brain Behav,2023,13(8):e3093.
[27]Ren B, Zhang ZS, Liu WW, et al. Surgical outcomes following encephaloduroarteriosynangiosis in adult moyamoya disease associated with type 2 diabetes. J Neurosurg,2016,125(2):308-314.
[28]胡绘平,刘文春,肖龙敏.脑硬膜颞浅动脉血管融通术联合中频电疗仪对缺血性烟雾病患儿的临床疗效.实用临床医药杂志,2021,25(22):95-98.
[29]Prabhakaran S, Liebeskind DS, Cotsonis G, et al. Predictors of early infarct recurrence in patients with symptomatic intracranial atherosclerotic disease. Stroke,2021,52(6):1961-1966.
[30]Jia B, Zhang X, Ma N, et al. Comparison of drugeluting stent with baremetal stent in patients with symptomatic highgrade intracranial atherosclerotic stenosis: a randomized clinical trial. JAMA Neurol,2022,79(2):176-184.
[31]Wabnitz AM, Derdeyn CP, Fiorella DJ, et al. Hemodynamic markers in the anterior circulation as predictors of recurrent stroke in patients with intracranial stenosis. Stroke,2019,50(1):143-147.
[32]Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Aggressive medical treatment with or without stenting in highrisk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet,2014,383(9914):333-341.
[33]Zaidat OO, Fitzsimmons BF, Woodward BK, et al. Effect of a balloonexpandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA,2015,313(12):1240-1248.
[34]QuinteroConsuegra MD, Toscano JF, Babadjouni R, et al. Encephaloduroarteriosynangiosis averts stroke in atherosclerotic patients with borderzone infarct: post hoc analysis from a performance criterion phase Ⅱ trial. Neurosurgery,2021,88(4):E312-E318.
[35]Zhang Q, Li Y, Tong H, et al. Comparison of therapeutic efficacy between isolated encephaloduroarteriosynangiosis and medical treatment in patients with atherosclerotic middle cerebral artery occlusion. World Neurosurg,2018,117:e483-e492.
[36]Dusick JR, Liebeskind DS, Saver JL, et al. Indirect revascularization for nonmoyamoya intracranial arterial stenoses: clinical and angiographic outcomes. J Neurosurg,2012,117(1):94-102.
[37]Gonzalez NR, QuinteroConsuegra MD, Chan JL, et al. Costeffectiveness analysis of encephaloduroarteriosynangiosis surgery for symptomatic intracranial atherosclerotic disease. Neurosurgery,2022,90(4):495-500.
[38]Gonzalez NR, Jiang H, Lyden P, et al. Encephaloduroarteriosynangiosis(EDAS) revascularization for symptomatic intracranial atherosclerotic stenoocclusive(ERSIAS) PhaseⅡ objective performance criterion trial. Int J Stroke,2021,16(6):701-709.
[39]Bao XY, Zhang Y, Wang QN, et al. Longterm outcomes after encephaloduroarteriosynangiosis in adult patients with moyamoya disease presenting with ischemia. World Neurosurg,2018,115:e482-e489.
[40]Kronenburg A, Bulder MMM, Bokkers RPH, et al. Cerebrovascular reactivity measured with ASL perfusion MRI, ivy sign, and regional tissue vascularization in moyamoya. World Neurosurg,2019,125:e639-e650.
[41]Yuan X, Yu H, Sun Z, et al. Evaluation of surgical revascularization procedure outcomes for adult moyamoya disease: a computed tomography perfusionbased study. Insights Imaging,2023,14(1):184.
[42]Lu M, Zhang H, Liu S, et al. Longterm outcomes of moyamoya disease versus atherosclerosisassociated moyamoya vasculopathy using highresolution MR vessel wall imaging. J Neurol Neurosurg Psychiatry,2023,94(7):567-574.
[43]Wang JZ, Mu J, Zhang D, et al. Clinical use of color Doppler ultrasonography to predict and evaluate the collateral development of two common revascularizations in patients with moyamoya disease. Front Neurol,2022,13:976695.